SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst heightened competitive concerns following Amazon Pharmacy's direct offering of Novo Nordisk's GLP-1 weight loss pill, which many in the community view as a significant headwind. While a vocal bearish contingent cites overvaluation and predicts further downside, a segment of investors sees current price levels as a strong buying opportunity, banking on the company's diversified telehealth platform and international expansion. The market is actively debating HIMS's growth trajectory and valuation as it navigates this evolving competitive landscape.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing a surge in attention following positive FDA feedback, which significantly de-risks its lead asset sonelokimab by clarifying a direct regulatory pathway without additional trials. This catalyst, combined with notable insider buying and multiple analyst upgrades, is driving strong community sentiment and fueling speculation for an imminent buyout or substantial re-rating in the competitive immunology market.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is experiencing extreme volatility and massive gains, largely fueled by a significant special cash dividend and discussions around a potential pivot to blockchain-based assets. The community is intensely focused on short squeeze potential and the dividend's impact, though many debate the company's underlying fundamentals against the backdrop of its dramatic price movements.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with investors expressing a mix of frustration over recent stock performance and renewed optimism for Briumvi's competitive standing. The community is actively discussing a competitor's recent regulatory setback, which highlights Briumvi's favorable profile, while anticipating potential strategic updates from the upcoming J.P. Morgan Healthcare Conference.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating U.S. actions in Venezuela, including military operations and blockades, create market uncertainty. Investors are sharply divided: some anticipate a significant oil price surge due to supply disruptions, while others predict eventual price stabilization or declines if new Venezuelan supply comes online and global oversupply persists. The financial community is closely watching the geopolitical implications of this evolving situation.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending as unseasonably warm weather continues to dampen heating demand, driving natural gas prices to multi-week lows. This sharp decline has fueled widespread frustration and significant losses among long holders, who are fiercely debating whether a bottom is in or if an anticipated "polar vortex" can ignite a major rebound against the ETF's inherent decay.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited is experiencing intense trading activity following news of a significant private placement and an acquisition, coinciding with the expiration of its IPO lock-up period. This low-float international stock is generating widespread community discussion, with many anticipating a substantial short squeeze and comparing its trajectory to other highly volatile market movers. However, considerable caution is also being voiced, highlighting the speculative nature and potential for rapid price movements.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is currently trending with significant community discussion around its recently announced token burn proposal, aiming for deflationary tokenomics, and a new roadmap. Despite a recent delisting, strong bullish sentiment persists due to its perceived low market cap and continued presence on major exchanges, with many anticipating substantial upside as a liquid staking protocol.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently trending due to a significant agreement with Meta Platforms to develop a nuclear energy campus in Ohio, aimed at powering future AI data centers. This deal, alongside anticipated DOE support for fuel and recent discussions on nuclear energy, has fueled intense bullish sentiment regarding the future of small modular reactors for AI infrastructure, despite some community concerns over current revenue and regulatory timelines.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is a major talking point as geopolitical shifts in Venezuela, including reports of US influence over its oil sector, ignite discussions about potential supply changes. This development is fueling community debate, with many anticipating a significant energy sector breakout and capital rotation, while others remain cautious about long-term infrastructure challenges and potential oversupply impacts on oil prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations

AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.

Are Investors Undervaluing CorMedix (CRMD) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines. 

<ul class="summary-bullets"><li>Investors brace for twin triggers in trade today: December jobs data and potential Supreme Court ruling on the legality of tariffs.&nbsp;</li><li>The jobs data is expected to dictate whether the Federal Reserve continues its aggressive pivot or hits the brakes on rate cuts.</li><li>Retail sentiment on Stocktwits showed caution toward SPY, while bullishness around tech-heavy QQQ intensified.</li></ul>U.S. stock futures were signaling a cautious start early Friday, with investors watching for two crucial triggers: December jobs data and a potential U.S. Supreme Court ruling on the legality of President Donald Trump’s tariff authority. This verdict could have wide implications for markets and trade policy. As of 3:30 a.m. ET on Friday, Nasdaq 100 futures, S&amp;P 500 futures, Dow futures and the Russell 2000 futures traded flat.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘neutral’ from ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has flipped back to ‘extremely bullish’ from ‘bullish’ a day ago, amid high message volumes.Trending Stocks To Watch Nvidia (NVDA): TSMC, its key manufacturing partner, reported a roughly 20% rise in revenue. Intel (INTC): Trump said he had a ‘great meeting’ with CEO Lip-Bu Tan yesterday.&nbsp;Chevron (CVX), Exxon Mobil (XOM), and SLB (SLB): Stocks are in focus after reports that senior executives from major oil companies are set to meet President Donald Trump, raising expectations around energy policy and domestic production.Disney (DIS): China’s Vice Premier Ding Xuexiang reportedly met Disney CEO Bob Iger in Beijing, encouraging further investment.&nbsp;Glencore (GNLCY): Reports suggest that Rio Tinto is in early talks with Glencore about a potential tie-up that could create the world’s largest mining company, with a combined valuation of nearly $207 billion.General Motors (GM): The company disclosed $7.1 billion in special charges tied to scaling back EV ambitions and restructuring its China operations.Tilray Brands (TLRY): Posted record fiscal Q2 revenue of $218 million, beating Street estimates.&nbsp;Johnson &amp; Johnson (JNJ):&nbsp;Has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-cuts-deal-with-trump-s-white-house-to-slash-drug-prices-and-dodge-tariffs/cmU2GbnR45p">secured</a> a tariff exemption in exchange for lower drug prices and two new U.S. manufacturing plants as part of its $55B domestic investment plan.&nbsp;CorMedix Therapeutics (CRMD): The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cor-medix-stock-rises-after-hours-ceo-locks-in-chairman-seat-bigger-paycheck-and-rich-severance/cmU2TRJR45s">disclosed</a> an expanded role and revised employment terms for CEO Joseph Todisco, following a sharp selloff earlier in the session tied to cautious guidance.Oscar Health: Shares rose nearly 7% after hours after gaining about 3% in regular trading, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">investors reacted to a House vote backing</a> ACA subsidy extensions, despite a disclosed insider share sale.Opendoor Technologies (OPEN), Rocket Companies (RKT), Offerpad Solutions (OPAD), UWM Holdings (UWMC): U.S. President Donald Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rkt-stock-rallies-on-trump-pledge-to-keep-mortgage-rates/cmU2R4KR45A">said</a> Thursday that he is working to lower mortgage rates for Americans, following several years of elevated borrowing costs.Monte Rosa Therapeutics (GLUE): Shares are in focus after the biotech priced a $300M public offering at $24 per share.&nbsp;Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;Ondas Holdings&nbsp;(<a href="https://stocktwits.com/news-articles/markets/equity/onds-stock-soars-to-5-year-highs-on-israel-defense-tie-ups-rebrand-buzz/cmUcUPnR45V">ONDS</a>),&nbsp;Oscar Health Inc. (<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">OSCR</a>), Security Matters (SMX), Baidu (BIDU), Him &amp; Hers Health (HIMS), among others.&nbsp;&nbsp; Other Catalysts To Watch On the economic front, investors are looking ahead to the release of the December Jobs Report at 8:30 a.m. ET. Economists expect the unemployment rate to tick down to 4.5%. Traders will also be listening closely to FOMC Member Neel Kashkari, who is scheduled to speak at 10:00 a.m. ET.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD Are On Traders' Radar Today

Early signals show futures flat, SPY sentiment cooling, and tech traders turning bullish.

Equity

Early signals show futures flat, SPY sentiment cooling, and tech traders turning bullish.


<ul class="summary-bullets"><li>The stock rose after a sharp selloff earlier in the session tied to cautious 2026 guidance.</li><li>Analysts flagged a steeper-than-expected slowdown in DefenCath revenue.</li><li>A new CEO employment agreement appeared to help steady investor sentiment following the drop.</li></ul>Shares of CorMedix Therapeutics rose in after-hours trading on Thursday after the company disclosed an expanded role and revised employment terms for CEO Joseph Todisco, following a sharp selloff earlier in the session tied to cautious guidance.The stock climbed nearly 1% in after-hours trading on Thursday after crashing 33% in the regular session to log its worst session in over three years.&nbsp;<h2 class="st-heading-2">CEO Elevated To Chairman With Pay Boost</h2>CorMedix said it entered into an amended and restated employment agreement with Todisco on Monday. Under the agreement, Todisco will continue as CEO and will also serve as chairman of the board, effective Thursday.&nbsp;Todisco’s annual base salary increases to $750,000 from $665,000, effective Jan. 1. His target annual bonus opportunity rises to 75% of base salary from 65%, beginning with fiscal 2026, with payouts based on company and individual objectives set by the board or its compensation committee. He remains eligible for equity awards under the company’s omnibus stock incentive plan as well.&nbsp;<h2 class="st-heading-2">Rich Exit Terms Kick In Under New CEO Deal</h2>If terminated without cause or for good reason, and subject to a customary release, Todisco would receive 18 months of base salary continuation, a prorated annual bonus based on actual performance, subsidized Consolidated Omnibus Budget Reconciliation Act (COBRA) premiums for up to 18 months, acceleration of certain near-term unvested equity awards, and any unpaid prior-year bonus.&nbsp;If termination occurs within 24 months of a corporate transaction, severance increases to 200% of base salary plus target bonus paid over 24 months, COBRA subsidies extend to 24 months, and all unvested equity awards fully accelerate.&nbsp;<h2 class="st-heading-2">DefenCath Reality Check</h2>On Thursday, CorMedix&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-crash-28-today/cmUbayOR45b">issued a cautious 2026 outlook</a>, warning revenue could come in below 2025 levels. Following the outlook, Truist Securities lowered its price target to $16 from $20 while maintaining a ‘Buy’ rating, noting that 2026 revenue guidance was roughly 40% below Street expectations and that 2027 DefenCath revenue guidance was about half of its initial estimate.&nbsp;Truist said this implied a greater tail-off in DefenCath revenue than previously factored and added it expects more detail at the company’s Feb. 10 investor day.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CorMedix was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/crmd_ss_png_5aaf19cbd0.webp" alt="crmd ss.png" width="968" height="144"><figcaption>TSLA sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure>One user said they bought 1,000 shares at $7.42, viewed the stock as oversold despite positive cash flow, and planned to sell above $8.<stembedurl>https://stocktwits.com/DSL12345/message/641298854</stembedurl>Another user noted that price targets remain above $15 and that the stock is currently trading at a 50% discount.<stembedurl>https://stocktwits.com/coveredcall123/message/641298735</stembedurl><a href="https://stocktwits.com/symbol/CRMD">CorMedix’s stock</a> has declined 31% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance

Joseph Todisco’s annual base salary increases to $750,000 from $665,000, effective Jan. 1.

CorMedix's (CRMD) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $14.00 price objective on shares of CorMedix in a research note on Thursday...

GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies

GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.

CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois

Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.

CorMedix (NASDAQ:CRMD) Shares Gap Down - What's Next?

CorMedix (NASDAQ:CRMD) Shares Gap Down - Time to Sell...

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRMD News

CRMDCorMedix Inc